Abstract: Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of large B⁃cell lymphoma, with a poor prognosis without standardized treatment protocols. Traditional therapeutic strategies, such as chemotherapy, proteasome inhibitors, immunomodulatory agents, CD30 and CD38 monoclonal antibodies, and autologous hematopoietic stem cell transplantation, have yielded suboptimal outcomes. Chimeric antigen receptor T (CAR⁃T) cell therapy has revolutionized the management of diffuse large B⁃cell lymphoma and multiple myeloma, offering hope for patients with PBL. However, clinical experience and data evidence supporting the application of CAR⁃T cell in PBL treatment remain scant. This paper reports a case of an elderly patient with PBL who achieved a complete response following B⁃cell maturation antigen CAR⁃T cell therapy. 

Key words: Plasmablastic lymphoma, Chimeric antigen receptor T-cell, B?cell maturation antigen, Relapsed, Refractory